WHO Prequalification Programme
WHO PUBLIC ASSESSMENT REPORT (WHOPAR)

[CV009 trade name]*

Molnupiravir 200 mg capsules

[CV009 trade name], manufactured at Dr. Reddy's Laboratories Limited, Ranga Reddy District, Telangana, India, was included in the WHO list of prequalified medicinal products for the treatment of COVID-19 on 17 April 2023.

[CV009 trade name] is indicated for COVID-19. Detailed information on the use of this product is described in the summary of product characteristics (SmPC), which can be found in this WHOPAR.

The active pharmaceutical ingredient of [CV009 trade name] is molnupiravir.

The efficacy and safety of molnupiravir are established based on clinical experience in the treatment of COVID-19.

For details on the uses of this product and for side effects and warnings, see Part 4 of this WHOPAR (summary of product characteristics).

On the basis of data submitted and public information on the use of molnupiravir in COVID-19, the team of assessors advised that [CV009 trade name] is of acceptable quality, efficacy and safety to allow inclusion of [CV009 trade name] in the list of prequalified medicinal products.

Summary of prequalification status for [CV009 trade name]:

Initial acceptance	**Date**	**Outcome**
Status on PQ list	17 April 2023	listed
Quality	25 October 2022	MR
Bioequivalence	26 October 2022	MR
Safety, efficacy	NA	NA
GMP (re-)inspection		
API	26 July 2022	MR*
FPP	24 June 2022	MR
GCP/GLP (re-)inspection	17 March 2023	MR

API: active pharmaceutical ingredient
FPP: finished pharmaceutical product
GCP: good clinical practice [quality standard]
GLP: good laboratory practice [quality standard]
GMP: good manufacturing practice [quality standard]
MR: meets requirements
MR*: desk review (based on recent inspection reports)
NA: not applicable, not available
PQ: prequalification

The table represents the status of relevant completed activities only.

* Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility.